The identification of biomarkers of cancer risk, treatment response and progression, including genetic polymorphisms, epigenetic alterations, infectious agents and aberrant levels of proteins, hormones and nutrients has become an increasingly important aim of investigators with peer-reviewed funding at Fox Chase Cancer Center (FCCC), The Cancer Prevention Biomarker and Genotyping Facility (CPBGF) was established in 2001 as a developing Core Facility and provides a centralized resource for cost-effective genotyping services and biomarker assays to support research-based human population and mouse studies. Genotyping services include the analysis of polymorphic variation and mutations within normal or tumor DMA utilizing state-of-the-art instrumentation and technology. Assessment of host genotype and tissue-specific alterations in DNA sequence aids in identifying predictive genetic biomarkers of cancer risk and treatment response as well as surrogate endpoints for chemoprevention. Mouse genotyping services also aid researchers in the breeding and maintenance of their transgenic and knockout strains. In addition to genotyping, the Facility performs assays for the analysis of potential environmental and behavioral biomarkers of cancer risk (i.e., tobacco metabolites and bisphenol) as well as dietary factors, which can be measured in tissues and biofluids. This new Core Facility is directed by Cynthia Spittle, Ph.D. Since its inception in 2001, the Facility has provided services for a total of 18 FCCC investigators in six Research Programs in all three Divisions. In 2003, >94% of usage was from investigators with peer-reviewed funding. There has been >200% increase in the number of genotyping assays performed during the first three years of operation. The services provided by the CPBGF benefit clinicians, epidemiologists and behavioral scientists with interests in cancer prevention and pharmacogenetics research and basic scientists who utilize mouse models in their work. The demand for genotyping and biomarker analyses is expected to continue to grow over the next five years. The CPBGF offers distinctive and non-duplicative services that are a vital addition to the support offered to investigators with peer-reviewed funding. During the next five years, the CPBGF will expand its services, staffing, and infrastructure in a cost-effective manner in order to best meet the needs of investigators with peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-47
Application #
7881799
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
47
Fiscal Year
2009
Total Cost
$133,005
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298

Showing the most recent 10 out of 1280 publications